Comparing the current results to its competitors, Lifecore Biomedical Inc reported Revenue decrease in the 1 quarter 2026 year on year by -35.54 %, despite the revenue increase by the most of its competitors of 45.45 %, recorded in the same quarter.
Lifecore Biomedical Inc 's Comment on Competition and Industry Peers
Lifecore operates in the contract development and manufacturing organization (CDMO) market for pharmaceuticals, which is highly competitive and regulated. Its competitors include full-service contract manufacturers as well as larger pharmaceutical, biotechnology, and specialty companies capable of insourcing manufacturing. Some pharmaceutical companies are divesting manufacturing capacity, which may be acquired by Lifecore's competitors. Several competitors are significantly larger and global, with greater financial, marketing, technical, and other resources than Lifecore.
October 29, 2025
Lifecore Biomedical: Navigating Challenges and Opportunities in the Injectable Pharmaceutical Market Lifecore Biomedical Inc., a prominent player in the biotechnology sector, recently made strides in securing its position within the competitive injectable pharmaceutical landscape by partnering with a leading global pharmaceutical company. This collaboration aims to execute a commercial site transfer, further establishing Lifecore as a preferred supplier of injectable products. However, amidst this advancement, the company faced challenges, reporting a year-over-year revenue decrease in the second quarter of 2025. This article examines Lifecore’s recent partnership, financial performance, market trends, an...
September 19, 2024
for CSIMarket.com In recent months, numerous class action lawsuits have been initiated against various companies, including Lifecore Biomedical, Inc. (NASDAQ: LFCR), Spire Global, Inc. (NYSE: SPIR), DexCom, Inc. (NASDAQ: DXCM), Arbor Realty Trust, Inc. (NYSE: ABR), and Oddity Tech (NASDAQ: ODD). These actions, led by notable investor rights law firms such as Bragar Eagel and Squire, P.C. and Rosen Law Firm, underline ongoing legal challenges and obligations faced by these publicly traded entities. Overview of Class ActionsClass action lawsuits enable groups of investors to collectively seek remedy against companies alleged to have committed fraud or misrepresentation affecting stock value. In this contex...
September 1, 2024
Shareholder Turbulence: Lifecore, Spire Global, Oddity Tech, and Arbor Realty Face Legal Scrutiny It seems these are trying times for investors linked to Lifecore Biomedical, Inc. (NASDAQ: LFCR), Spire Global, Inc. (NYSE: SPIR), Oddity Tech (NASDAQ: ODD), and Arbor Realty Trust, Inc. (NYSE: ABR). Renowned shareholder rights law firm Bragar Eagel and Squire, P.C. has launched class action lawsuits against these companies, underscoring the increasing strain between shareholders and corporate governance. Investors are being called upon to come forward and join the legal fray. A Wave of LitigationThe legal battle first saw light early August 2024, when Bragar Eagel and Squire announced lawsuits against Lifecore...
August 5, 2024
Class action lawsuits are an essential component of the shareholder rights landscape, often serving to highlight corporate governance issues, financial misrepresentations, or breaches of fiduciary duty. Recently, Bragar Eagel and Squire, P.C., a well-known law firm focusing on shareholder involvement, announced that class action lawsuits have been initiated against four companies: Lifecore Biomedical, Inc. (NASDAQ: LFCR), Seritage Growth Properties (NYSE: SRG), Oddity Tech (NASDAQ: ODD), and Arbor Realty Trust, Inc. (NYSE: ABR). In this article, we will outline the key facts surrounding these lawsuits and assess their potential impact on the companies involved. Background on the Companies- Lifecore Biomedi...
July 1, 2024
In a dynamic pharmaceutical landscape, leadership and strategic direction become key drivers of an organization s success. Lifecore Biomedical s recent cooperation agreement with 22NW, marking the induction of four high-profile board members, brings a palpable wave of renewed vision, expertise, and leadership capability. This article outlines the factual basis of the agreement and assesses its potential impacts on Lifecore Biomedical s future endeavors. Lifecore Biomedical, a distinguished name in the pharmaceutical and biotech sectors, has recently announced a pivotal cooperation agreement with 22NW, a strategic investment group. This collaboration underscores a tactical expansion of Lifecore’s board of...
Ardelyx Inc is a biopharmaceutical company that focuses on the development of novel, minimally-absorbed small molecules to treat gastrointestinal diseases. Their business model revolves around identifying specific needs within the gastrointestinal field and leveraging their research and development capabilities to create innovative therapeutic solutions. By partnering with other pharmaceutical companies and pursuing strategic collaborations, Ardelyx aims to bring its products to market and ultimately improve patient outcomes in the gastrointestinal space.
EQT Corporation operates as a natural gas production company, focusing on the exploration, development, and production of natural gas resources in the Appalachian Basin. The company follows an integrated business model that involves the acquisition of properties, drilling, completion, and operational activities to extract natural gas efficiently.
Evolus Inc is a pharmaceutical company that operates in the field of aesthetics, with a primary focus on developing and commercializing minimally invasive treatments for patients. Their business model revolves around researching and developing innovative neurotoxin products to address various facial aesthetic concerns. The company aims to bring their products to market through strategic partnerships with healthcare professionals and providers, ensuring widespread accessibility and utilization.
Bausch Health Companies Inc operates through three segments: Bausch + Lomb/International, Salix, and Ortho Dermatologics. The company focuses on developing, manufacturing, and marketing a wide range of pharmaceutical products, medical devices, and over-the-counter products primarily in the areas of eye health, gastroenterology, and dermatology. Bausch Health aims to provide innovative and quality healthcare solutions to improve patients' lives globally.
Biodexa Pharmaceuticals Plc operates as a biopharmaceutical company that focuses on the research, development, and commercialization of innovative medical solutions. Their business model revolves around leveraging scientific expertise to bring new medicines to market and meet the healthcare needs of patients worldwide.
Sources:
Lifecore Biomedical Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lifecore Biomedical Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
